Ann: PIIb DMD trial approved in Bulgaria- UK, Australia advancing, page-25

I just had a light bulb moment !
Could it be that our chair CG has been in talks with us he FDA .
Because of the Urgent need for the DMD population
and our fantastic results from our last DMD trial
The FDA agreed that the end points will be what we achieved PUL -2 in the last trial.
So with the 9 month Tox study already underway and the 12 month study in Belgium, Turkey , Uk and Aust
being completed and successful: it will be enough to market in Europe and the US.
To me : it makes sense.
Great for the DMD population.
This is only my opinion/ have a gut feeling that this is what will happen .